CPPD is notoriously difficult to diagnose due to its diverse presentations & uncertain etiology. Recent advances have helped rheumatologists better understand its risk factors, classify, diagnose & treat the condition.
Researchers Scholosstein et al were first to connection HLA antigens to the inflammatory disease, not Brewerton et al as reported [The Rheumatologist, May 2014]
Drug’s antiinflammatory properties may help alleviate pain in patients with OA, reduce risk of myocardial infarction, but toxicity, drug interactions need to be considered
Better understanding of goals, effect of gout therapy with nonsteroidal anti-inflammatory drugs, urate lowering medication needed to improve quality of care